Completed PHASE1 INTERVENTIONAL 2-arm NCT02201303

Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression

A Single-Center In Vitro Study to Evaluate GSK1325756 Inhibition of CD11b Cell Surface Expression in Healthy Adults and Respiratory Syncytial Virus-Infected Children <2 Years (200591)

Sponsor: GlaxoSmithKline

Conditions Infections, Respiratory Syncytial Virus

Interventions CXCL1 Danirixin

Updated 7 times since 2017 Last updated: May 5, 2017 Started: Jan 13, 2014 Primary completion: Jul 2, 2015 Completion: Jul 2, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02201303, this PHASE1 trial focuses on Infections, Respiratory Syncytial Virus and remains completed. Sponsored by GlaxoSmithKline, it has been updated 7 times since 2014, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jul 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jul 2017 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Syracuse, United States